Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapies are typically administered by injection every few weeks, while Enlicitide was administered orally as a once-daily 20 mg pill in the 2025 trial.
November 21, 2025
high
comparative
Modes of administration for lipid-lowering therapies compared to the oral dosing regimen used for Enlicitide in the trial.